{"title":"骨髓移植受者腺病毒膀胱炎诱导的一过性狼疮抗凝剂。","authors":"Tatsuya Imi, Hidesaku Asakura, Keijiro Sato, Shinya Yamada, Takeshi Yoroidaka, Yoshitaka Zaimoku, Hiroyuki Maruyama, Kohei Hosokawa, Akiyo Yoshida, Hiroyuki Takamatsu, Ken Ishiyama, Hirohito Yamazaki, Hikaru Kobayashi, Shinji Nakao, Toshihiro Miyamoto","doi":"10.1007/s12185-025-04020-1","DOIUrl":null,"url":null,"abstract":"<p><p>Adenovirus-associated hemorrhagic cystitis (AdV-HC) is a serious complication of hematopoietic stem cell transplantation (HSCT) that requires hemostatic therapies to control severe hematuria. Here we present the case of a 65-year-old woman with acute myeloid leukemia who successfully underwent HSCT, but developed AdV-HC followed by adenovirus viremia. Marked prolongation of activated partial thromboplastin time (APTT) was observed, along with a decrease in all coagulation factors except prothrombin, raising suspicion of a coagulation factor deficiency. A workup including the APTT cross-mixing test, diluted Russell's viper venom time, and phospholipid neutralization assays revealed the presence of lupus anticoagulant (LA), indicating a thrombotic tendency due to LA associated with artifactual lowering of coagulation factors. Based on these findings, no hemostatic agents were used to manage macroscopic hematuria, and all coagulation test results spontaneously normalized with the resolution of adenovirus viremia, without any thrombus formation. Patients with AdV-HC and prolonged APTT should be screened for LA to avoid inappropriate use of hemostatic agents.</p>","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"605-610"},"PeriodicalIF":1.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476403/pdf/","citationCount":"0","resultStr":"{\"title\":\"Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.\",\"authors\":\"Tatsuya Imi, Hidesaku Asakura, Keijiro Sato, Shinya Yamada, Takeshi Yoroidaka, Yoshitaka Zaimoku, Hiroyuki Maruyama, Kohei Hosokawa, Akiyo Yoshida, Hiroyuki Takamatsu, Ken Ishiyama, Hirohito Yamazaki, Hikaru Kobayashi, Shinji Nakao, Toshihiro Miyamoto\",\"doi\":\"10.1007/s12185-025-04020-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Adenovirus-associated hemorrhagic cystitis (AdV-HC) is a serious complication of hematopoietic stem cell transplantation (HSCT) that requires hemostatic therapies to control severe hematuria. Here we present the case of a 65-year-old woman with acute myeloid leukemia who successfully underwent HSCT, but developed AdV-HC followed by adenovirus viremia. Marked prolongation of activated partial thromboplastin time (APTT) was observed, along with a decrease in all coagulation factors except prothrombin, raising suspicion of a coagulation factor deficiency. A workup including the APTT cross-mixing test, diluted Russell's viper venom time, and phospholipid neutralization assays revealed the presence of lupus anticoagulant (LA), indicating a thrombotic tendency due to LA associated with artifactual lowering of coagulation factors. Based on these findings, no hemostatic agents were used to manage macroscopic hematuria, and all coagulation test results spontaneously normalized with the resolution of adenovirus viremia, without any thrombus formation. Patients with AdV-HC and prolonged APTT should be screened for LA to avoid inappropriate use of hemostatic agents.</p>\",\"PeriodicalId\":13992,\"journal\":{\"name\":\"International Journal of Hematology\",\"volume\":\" \",\"pages\":\"605-610\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476403/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12185-025-04020-1\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12185-025-04020-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.
Adenovirus-associated hemorrhagic cystitis (AdV-HC) is a serious complication of hematopoietic stem cell transplantation (HSCT) that requires hemostatic therapies to control severe hematuria. Here we present the case of a 65-year-old woman with acute myeloid leukemia who successfully underwent HSCT, but developed AdV-HC followed by adenovirus viremia. Marked prolongation of activated partial thromboplastin time (APTT) was observed, along with a decrease in all coagulation factors except prothrombin, raising suspicion of a coagulation factor deficiency. A workup including the APTT cross-mixing test, diluted Russell's viper venom time, and phospholipid neutralization assays revealed the presence of lupus anticoagulant (LA), indicating a thrombotic tendency due to LA associated with artifactual lowering of coagulation factors. Based on these findings, no hemostatic agents were used to manage macroscopic hematuria, and all coagulation test results spontaneously normalized with the resolution of adenovirus viremia, without any thrombus formation. Patients with AdV-HC and prolonged APTT should be screened for LA to avoid inappropriate use of hemostatic agents.
期刊介绍:
The International Journal of Hematology, the official journal of the Japanese Society of Hematology, has a long history of publishing leading research in hematology. The journal comprises articles that contribute to progress in research not only in basic hematology but also in clinical hematology, aiming to cover all aspects of this field, namely, erythrocytes, leukocytes and hematopoiesis, hemostasis, thrombosis and vascular biology, hematological malignancies, transplantation, and cell therapy. The expanded [Progress in Hematology] section integrates such relevant fields as the cell biology of stem cells and cancer cells, and clinical research in inflammation, cancer, and thrombosis. Reports on results of clinical trials are also included, thus contributing to the aim of fostering communication among researchers in the growing field of modern hematology. The journal provides the best of up-to-date information on modern hematology, presenting readers with high-impact, original work focusing on pivotal issues.